Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men

This publication has 10 references indexed in Scilit:

• In vivo method for quantitation of anti-platelet potency of drugs
  Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1978
• Sulfinpyrazone in the Prevention of Cardiac Death after Myocardial Infarction
  New England Journal of Medicine, 1978
• The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbits
  Prostaglandins, 1977
• PLATELET ACTIVATION IN ACUTE CEREBRAL ISCHÆMIA
  The Lancet, 1977
• Modulation of human platelet adenylate cyclase by prostacyclin (PGX)
  Prostaglandins, 1977
• Prostacyclin (PGX) is the endogeneous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid
  Prostaglandins, 1977
• Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides
  Prostaglandins, 1976
• An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
  Nature, 1976
• Aspirin as an Antiplatelet Agent: Template Bleeding Time as a Monitor of Therapy
  American Journal of Clinical Pathology, 1973